202 related articles for article (PubMed ID: 25370705)
1. Classification of tumor area using combined DCE and DSC MRI in patients with glioblastoma.
Artzi M; Blumenthal DT; Bokstein F; Nadav G; Liberman G; Aizenstein O; Ben Bashat D
J Neurooncol; 2015 Jan; 121(2):349-57. PubMed ID: 25370705
[TBL] [Abstract][Full Text] [Related]
2. Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study.
Artzi M; Bokstein F; Blumenthal DT; Aizenstein O; Liberman G; Corn BW; Ben Bashat D
Eur J Radiol; 2014 Jul; 83(7):1250-1256. PubMed ID: 24809637
[TBL] [Abstract][Full Text] [Related]
3. Automatic multi-modal MR tissue classification for the assessment of response to bevacizumab in patients with glioblastoma.
Liberman G; Louzoun Y; Aizenstein O; Blumenthal DT; Bokstein F; Palmon M; Corn BW; Ben Bashat D
Eur J Radiol; 2013 Feb; 82(2):e87-94. PubMed ID: 23017192
[TBL] [Abstract][Full Text] [Related]
4. Differentiation between treatment-related changes and progressive disease in patients with high grade brain tumors using support vector machine classification based on DCE MRI.
Artzi M; Liberman G; Nadav G; Blumenthal DT; Bokstein F; Aizenstein O; Ben Bashat D
J Neurooncol; 2016 May; 127(3):515-24. PubMed ID: 26754857
[TBL] [Abstract][Full Text] [Related]
5. GPU-accelerated nonparametric kinetic analysis of DCE-MRI data from glioblastoma patients treated with bevacizumab.
Hsu YH; Ferl GZ; Ng CM
Magn Reson Imaging; 2013 May; 31(4):618-23. PubMed ID: 23200680
[TBL] [Abstract][Full Text] [Related]
6. MRI assessment of relapsed glioblastoma during treatment with bevacizumab: volumetric measurement of enhanced and FLAIR lesions for evaluation of response and progression--a pilot study.
Pichler J; Pachinger C; Pelz M; Kleiser R
Eur J Radiol; 2013 May; 82(5):e240-5. PubMed ID: 23399039
[TBL] [Abstract][Full Text] [Related]
7. Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival.
Hattingen E; Jurcoane A; Daneshvar K; Pilatus U; Mittelbronn M; Steinbach JP; Bähr O
Neuro Oncol; 2013 Oct; 15(10):1395-404. PubMed ID: 23925453
[TBL] [Abstract][Full Text] [Related]
8. On differentiation between vasogenic edema and non-enhancing tumor in high-grade glioma patients using a support vector machine classifier based upon pre and post-surgery MRI images.
Sengupta A; Agarwal S; Gupta PK; Ahlawat S; Patir R; Gupta RK; Singh A
Eur J Radiol; 2018 Sep; 106():199-208. PubMed ID: 30150045
[TBL] [Abstract][Full Text] [Related]
9. Uninterpretable Dynamic Susceptibility Contrast-Enhanced Perfusion MR Images in Patients with Post-Treatment Glioblastomas: Cross-Validation of Alternative Imaging Options.
Heo YJ; Kim HS; Park JE; Choi CG; Kim SJ
PLoS One; 2015; 10(8):e0136380. PubMed ID: 26296086
[TBL] [Abstract][Full Text] [Related]
10. Which combination of MR imaging modalities is best for predicting recurrent glioblastoma? Study of diagnostic accuracy and reproducibility.
Kim HS; Goh MJ; Kim N; Choi CG; Kim SJ; Kim JH
Radiology; 2014 Dec; 273(3):831-43. PubMed ID: 24885857
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of dynamic contrast-enhanced MRI derived microvascular permeability in recurrent glioblastoma treated with bevacizumab.
Kickingereder P; Wiestler B; Graf M; Heiland S; Schlemmer HP; Wick W; Wick A; Bendszus M; Radbruch A
J Neurooncol; 2015 Jan; 121(2):373-80. PubMed ID: 25359396
[TBL] [Abstract][Full Text] [Related]
12. Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab.
Leu K; Enzmann DR; Woodworth DC; Harris RJ; Tran AN; Lai A; Nghiemphu PL; Pope WB; Cloughesy TF; Ellingson BM
Cancer Imaging; 2014 Nov; 14(1):31. PubMed ID: 25608485
[TBL] [Abstract][Full Text] [Related]
13. MR Perfusion-derived Hemodynamic Parametric Response Mapping of Bevacizumab Efficacy in Recurrent Glioblastoma.
Kickingereder P; Radbruch A; Burth S; Wick A; Heiland S; Schlemmer HP; Wick W; Bendszus M; Bonekamp D
Radiology; 2016 May; 279(2):542-52. PubMed ID: 26579564
[TBL] [Abstract][Full Text] [Related]
14. Noncompartmental kinetic analysis of DCE-MRI data from malignant tumors: Application to glioblastoma treated with bevacizumab.
Port RE; Bernstein LJ; Barboriak DP; Xu L; Roberts TP; van Bruggen N
Magn Reson Med; 2010 Aug; 64(2):408-17. PubMed ID: 20665785
[TBL] [Abstract][Full Text] [Related]
15. Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas.
Piludu F; Marzi S; Pace A; Villani V; Fabi A; Carapella CM; Terrenato I; Antenucci A; Vidiri A
Neuroradiology; 2015 Dec; 57(12):1269-80. PubMed ID: 26364181
[TBL] [Abstract][Full Text] [Related]
16. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
[TBL] [Abstract][Full Text] [Related]
17. Human cerebral blood volume measurements using dynamic contrast enhancement in comparison to dynamic susceptibility contrast MRI.
Artzi M; Liberman G; Nadav G; Vitinshtein F; Blumenthal DT; Bokstein F; Aizenstein O; Ben Bashat D
Neuroradiology; 2015 Jul; 57(7):671-8. PubMed ID: 25845809
[TBL] [Abstract][Full Text] [Related]
18. Decrease in the apparent diffusion coefficient in peritumoral edema for the assessment of recurrent glioblastoma treated by bevacizumab.
Takano S; Kimu H; Tsuda K; Osuka S; Nakai K; Yamamoto T; Ishikawa E; Akutsu H; Matsuda M; Matsumura A
Acta Neurochir Suppl; 2013; 118():185-9. PubMed ID: 23564129
[TBL] [Abstract][Full Text] [Related]
19. Quantification of Radiomics features of Peritumoral Vasogenic Edema extracted from fluid-attenuated inversion recovery images in glioblastoma and isolated brain metastasis, using T1-dynamic contrast-enhanced Perfusion analysis.
Parvaze PS; Bhattacharjee R; Verma YK; Singh RK; Yadav V; Singh A; Khanna G; Ahlawat S; Trivedi R; Patir R; Vaishya S; Shah TJ; Gupta RK
NMR Biomed; 2023 May; 36(5):e4884. PubMed ID: 36453877
[TBL] [Abstract][Full Text] [Related]
20. MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy.
Jalali S; Chung C; Foltz W; Burrell K; Singh S; Hill R; Zadeh G
Neuro Oncol; 2014 Jun; 16(6):868-79. PubMed ID: 24759636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
